FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791041768> ?p ?o ?g. }

• W2791041768 endingPage "16058" @default.
• W2791041768 startingPage "16043" @default.
• W2791041768 abstract "Chemotherapeutic resistance evolves in about 70 % of ovarian cancer patients and is a major cause of death in this tumor entity. Novel approaches to overcome these therapeutic limitations are therefore highly warranted. A disintegrin and metalloprotease 17 (ADAM17) is highly expressed in ovarian cancer and required for releasing epidermal growth factor receptor (EGFR) ligands like amphiregulin (AREG). This factor has recently been detected in ascites of advanced stage ovarian cancer patients. However, it is not well understood, whether and how ADAM17 might contribute to chemo resistance of ovarian cancer. In this study, we identified ADAM17 as an essential upstream regulator of AREG release under chemotherapeutic treatment in ovarian cancer cell lines and patient derived cells. In the majority of ovarian cancer cells cisplatin treatment resulted in enhanced ADAM17 activity, as shown by an increased shedding of AREG. Moreover, both mRNA and the protein content of AREG were dose-dependently increased by cisplatin exposure. Consequently, cisplatin strongly induced phosphorylation of ADAM17-downstream mediators, the EGFR and extracellular signal-regulated kinases (ERK). Phorbol 12-myristate 13-acetate (PMA), similarly to cisplatin, mediated AREG shedding and membrane fading of surface ADAM17. Inhibition of ADAM17 with either GW280264X or the anti-ADAM17 antibody D1 (A12) as well as silencing of ADAM17 by siRNA selectively reduced AREG release. Thus, ADAM17 inhibition sensitized cancer cells to cisplatin-induced apoptosis, and significantly reduced cell viability. Based on these findings, we propose that targeting of ADAM17 in parallel to chemotherapeutic treatment suppresses survival pathways and potentially diminish evolving secondary chemo resistance mechanisms." @default.
• W2791041768 created "2018-03-29" @default.
• W2791041768 creator A5001663159 @default.
• W2791041768 creator A5008563937 @default.
• W2791041768 creator A5011261251 @default.
• W2791041768 creator A5011621128 @default.
• W2791041768 creator A5026742262 @default.
• W2791041768 creator A5044640003 @default.
• W2791041768 creator A5052373782 @default.
• W2791041768 creator A5061324093 @default.
• W2791041768 creator A5066649665 @default.
• W2791041768 creator A5070867470 @default.
• W2791041768 creator A5071027943 @default.
• W2791041768 creator A5080994672 @default.
• W2791041768 creator A5088720640 @default.
• W2791041768 date "2018-03-23" @default.
• W2791041768 modified "2023-09-23" @default.
• W2791041768 title "ADAM17 inhibition enhances platinum efficiency in ovarian cancer" @default.
• W2791041768 cites W134285098 @default.
• W2791041768 cites W1965147884 @default.
• W2791041768 cites W1982021610 @default.
• W2791041768 cites W1982692351 @default.
• W2791041768 cites W1987209094 @default.
• W2791041768 cites W1992301100 @default.
• W2791041768 cites W1992660677 @default.
• W2791041768 cites W1995242599 @default.
• W2791041768 cites W1997005830 @default.
• W2791041768 cites W2009477654 @default.
• W2791041768 cites W2009741112 @default.
• W2791041768 cites W2011826559 @default.
• W2791041768 cites W2012967865 @default.
• W2791041768 cites W2018221147 @default.
• W2791041768 cites W2021920896 @default.
• W2791041768 cites W2033207217 @default.
• W2791041768 cites W2038578669 @default.
• W2791041768 cites W2046028948 @default.
• W2791041768 cites W2048164934 @default.
• W2791041768 cites W2058729725 @default.
• W2791041768 cites W206131514 @default.
• W2791041768 cites W2061593125 @default.
• W2791041768 cites W2061943904 @default.
• W2791041768 cites W2067592016 @default.
• W2791041768 cites W2072219853 @default.
• W2791041768 cites W2076233716 @default.
• W2791041768 cites W2076483114 @default.
• W2791041768 cites W2090968329 @default.
• W2791041768 cites W2110870557 @default.
• W2791041768 cites W2114853101 @default.
• W2791041768 cites W2116561160 @default.
• W2791041768 cites W2119445810 @default.
• W2791041768 cites W2129033989 @default.
• W2791041768 cites W2130487791 @default.
• W2791041768 cites W2131091972 @default.
• W2791041768 cites W2135947389 @default.
• W2791041768 cites W2137573595 @default.
• W2791041768 cites W2141436693 @default.
• W2791041768 cites W2151628822 @default.
• W2791041768 cites W2159225854 @default.
• W2791041768 cites W2162222490 @default.
• W2791041768 cites W2167943497 @default.
• W2791041768 cites W2170928115 @default.
• W2791041768 cites W2171658624 @default.
• W2791041768 cites W2196212609 @default.
• W2791041768 cites W2255406080 @default.
• W2791041768 cites W2265368464 @default.
• W2791041768 cites W2387718408 @default.
• W2791041768 cites W2519148856 @default.
• W2791041768 cites W2528228811 @default.
• W2791041768 cites W2531416503 @default.
• W2791041768 cites W2563277046 @default.
• W2791041768 cites W2570618306 @default.
• W2791041768 cites W2571439955 @default.
• W2791041768 cites W2589500190 @default.
• W2791041768 cites W2611383873 @default.
• W2791041768 cites W4232995978 @default.
• W2791041768 doi "https://doi.org/10.18632/oncotarget.24682" @default.
• W2791041768 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5882316" @default.
• W2791041768 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29662625" @default.
• W2791041768 hasPublicationYear "2018" @default.
• W2791041768 type Work @default.
• W2791041768 sameAs 2791041768 @default.
• W2791041768 citedByCount "15" @default.
• W2791041768 countsByYear W27910417682018 @default.
• W2791041768 countsByYear W27910417682020 @default.
• W2791041768 countsByYear W27910417682021 @default.
• W2791041768 countsByYear W27910417682022 @default.
• W2791041768 countsByYear W27910417682023 @default.
• W2791041768 crossrefType "journal-article" @default.
• W2791041768 hasAuthorship W2791041768A5001663159 @default.
• W2791041768 hasAuthorship W2791041768A5008563937 @default.
• W2791041768 hasAuthorship W2791041768A5011261251 @default.
• W2791041768 hasAuthorship W2791041768A5011621128 @default.
• W2791041768 hasAuthorship W2791041768A5026742262 @default.
• W2791041768 hasAuthorship W2791041768A5044640003 @default.
• W2791041768 hasAuthorship W2791041768A5052373782 @default.
• W2791041768 hasAuthorship W2791041768A5061324093 @default.
• W2791041768 hasAuthorship W2791041768A5066649665 @default.
• W2791041768 hasAuthorship W2791041768A5070867470 @default.

• next